Literature DB >> 2835560

Prostanoids and cyclic nucleotides in malignant and benign ovarian tumors.

P K Heinonen1, T Metsä-Ketelä.   

Abstract

The concentrations of prostaglandin E2 (PGE2), 6-keto-PGF1 alpha, thromboxane B2(TxB2), cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in ovarian tumor tissue were measured in 38 post-menopausal women with malignant or benign ovarian tumor and in six women without ovarian neoplasm. PGE2 and TxB2 contents in ovarian cancer tissue were significantly (P less than 0.05) higher than in normal ovarian tissue. The prostanoids were also increased in the cyst fluid of epithelial malignant tumors compared to cyst fluids of benign ovarian tumors. Cyclic AMP concentrations in cancer tissue were lower than in non-malignant ovarian tissue, while the levels of cGMP were similar in all groups studied.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835560     DOI: 10.1007/BF03003177

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  19 in total

Review 1.  Platelet aggregation inhibitors and cancer metastasis.

Authors:  H Gastpar
Journal:  Ann Chir Gynaecol       Date:  1982

2.  Rapid assay of adenine nucleotides or creatine compounds in extracts of cardiac tissue by paired-ion reverse-phase high-performance liquid chromatography.

Authors:  E Juengling; H Kammermeier
Journal:  Anal Biochem       Date:  1980-03-01       Impact factor: 3.365

3.  A modified method for extraction and purification of prostaglandins with resin XAD-2.

Authors:  E Seppälä; O Pora; T Metsä-Ketelä
Journal:  Prostaglandins Leukot Med       Date:  1984-05

4.  Adenosine triphosphate conservation in metabolic regulation. Rat liver citrate cleavage enzyme.

Authors:  D E Atkinson; G M Walton
Journal:  J Biol Chem       Date:  1967-07-10       Impact factor: 5.157

5.  Fatty acid composition and arachidonic acid metabolites in ascitic fluid of patients with ovarian cancer.

Authors:  R Punnonen; E Seppälä; K Punnonen; P K Heinonen
Journal:  Prostaglandins Leukot Med       Date:  1986-05

6.  Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis.

Authors:  D W Cramer; W R Welch
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

Review 7.  Prostaglandins and cancer: a review of tumor initiation through tumor metastasis.

Authors:  K V Honn; R S Bockman; L J Marnett
Journal:  Prostaglandins       Date:  1981-05

8.  Prostacyclin: a potent antimetastatic agent.

Authors:  K V Honn; B Cicone; A Skoff
Journal:  Science       Date:  1981-06-12       Impact factor: 47.728

9.  LH(hCG) receptor in benign and malignant tumors of human ovary.

Authors:  H Rajaniemi; A Kauppila; L Rönnberg; K Selander; P Pystynen
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1981

10.  Prostaglandin and thromboxane production in ovarian cancer tissue.

Authors:  P K Heinonen; T Metsä-Ketelä
Journal:  Gynecol Obstet Invest       Date:  1984       Impact factor: 2.031

View more
  4 in total

1.  Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer.

Authors:  I Klapan; V Katić; F Culo; V Cuk
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  DHA induces apoptosis of human malignant breast cancer tissues by the TLR-4/PPAR-α pathways.

Authors:  Lijing Geng; Wei Zhou; Bing Liu; Xinyun Wang; Bo Chen
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

Review 3.  From purines to purinergic signalling: molecular functions and human diseases.

Authors:  Zhao Huang; Na Xie; Peter Illes; Francesco Di Virgilio; Henning Ulrich; Alexey Semyanov; Alexei Verkhratsky; Beata Sperlagh; Shu-Guang Yu; Canhua Huang; Yong Tang
Journal:  Signal Transduct Target Ther       Date:  2021-04-28

4.  The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment.

Authors:  Alexandra M Fajardo; Gary A Piazza; Heather N Tinsley
Journal:  Cancers (Basel)       Date:  2014-02-26       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.